NASDAQ · CLYM
Climb Bio, Inc.
$10.20-$0.14 (-1.31%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.33% below the high.
Loading market information…
NASDAQ · RVNC · USD
Stock price, earnings
Quote as of Feb 6, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Revance Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Revance Therapeutics, Inc. is a biotechnology company specializing in the research, manufacturing, and marketing of neuromodulators for diverse aesthetic and therapeutic uses across both domestic and international markets. The company's leading product candidate, DaxibotulinumtoxinA for injection, has concluded Phase III clinical evaluations for treating glabellar (frown) lines and cervical dystonia. This same drug is currently in Phase II clinical trials for addressing upper facial lines, moderate to severe dynamic forehead lines, and moderate to severe lateral canthal lines, following the successful completion of its Phase II trials for adult upper limb spasticity and plantar fasciitis. Beyond this, Revance is conducting preclinical studies for DaxibotulinumtoxinA as a potential migraine treatment and is developing a topical version for various indications. The company is also developing OnabotulinumtoxinA, intended as a biosimilar to BOTOX. A collaborative and licensing partnership with Viatris Inc. facilitates the development, manufacturing, and commercialization of onabotulinumtoxinA. Initially established in 1999 as Essentia Biosystems, Inc., the company officially rebranded as Revance Therapeutics, Inc. in April 2005 and maintains its corporate headquarters in Nashville, Tennessee.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:36 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $56.78M-2.79% vs estimate |
| Q2 2023 | Aug 8, 2023 | -$0.80-11.11% vs estimate | $58.13M-1.53% vs estimate |
|---|
| Q1 2023 | May 9, 2023 | -$0.74+1.33% vs estimate | $49.33M+7.01% vs estimate |
|---|
KEEP COMPARING
$10.20-$0.14 (-1.31%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.33% below the high.
$10.15+$0.02 (+0.2%)
iTeos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.43% below the high.
$8.44-$2.01 (-19.23%)
Big Cypress Acquisition Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.57% below the high.
$23.99-$0.01 (-0.04%)
Claritev Corporation’s quoted price sits in the lower half of its reported 52-week range, 67.44% below the high.
$2.10-$0.10 (-4.55%)
SomaLogic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.59% below the high.
$8.61+$0.02 (+0.23%)
Y-mAbs Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.55% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$7.16+$0.01 (+0.14%)
G1 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.42% below the high.
THE ANALYST VIEW
22 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
